{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:51:32Z","timestamp":1769557892943,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:00:00Z","timestamp":1568937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:00:00Z","timestamp":1568937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There has been a surging interest in the putative role of peripheral growth factors in the pathophysiology of fibromyalgia, specifically in the peripheral sensitization that occurs in chronic pain disorders. This cross-sectional study set out to assess and compare brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in plasma samples from fibromyalgia patients and healthy controls. Plasma BDNF and NGF were measured in 89 fibromyalgia patients and 36 pain-free controls, and compared using ANCOVA controlling for potential confounders, as well as Bayesian methods for parameter estimation and model evaluation. BDNF and NGF levels in fibromyalgia patients did not differ from those in pain-free controls. Statistical methods were consistent, with both frequentist and Bayesian approaches leading to the same conclusions. Our study fails to replicate the finding that peripheral BDNF is altered in fibromyalgia, and instead our findings suggest that plasma levels of growth factor appear normative in fibromyalgia.<\/jats:p>","DOI":"10.1038\/s41598-019-49403-7","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T10:15:48Z","timestamp":1568974548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["No evidence for altered plasma NGF and BDNF levels in fibromyalgia patients"],"prefix":"10.1038","volume":"9","author":[{"given":"David","family":"Baumeister","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Eich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Saft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Geisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Hellweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla I.","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Tesarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"key":"49403_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2009.09.006","volume":"122","author":"DJ Clauw","year":"2009","unstructured":"Clauw, D. J. Fibromyalgia: An Overview. Am. J. Med. 122, S3\u2013S13 (2009).","journal-title":"Am. J. Med."},{"key":"49403_CR2","first-page":"518","volume":"7","author":"T Schmidt-Wilcke","year":"2011","unstructured":"Schmidt-Wilcke, T. & Clauw, D. J. Fibromyalgia: From pathophysiology to therapy. Nature Reviews. Rheumatology 7, 518\u2013527 (2011).","journal-title":"Rheumatology"},{"key":"49403_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S1521-6942(03)00042-1","volume":"17","author":"JT Gran","year":"2003","unstructured":"Gran, J. T. The epidemiology of chronic generalized musculoskeletal pain. Best Practice and Research: Clinical Rheumatology 17, 547\u2013561 (2003).","journal-title":"Best Practice and Research: Clinical Rheumatology"},{"key":"49403_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1517\/14728222.2014.994506","volume":"19","author":"J Nijs","year":"2015","unstructured":"Nijs, J. et al. Brain-derived neurotrophic factor as a driving force behind neuroplasticity in neuropathic and central sensitization pain: a new therapeutic target? Expert Opin. Ther. Targets 19, 565\u2013576 (2015).","journal-title":"Expert Opin. Ther. Targets"},{"key":"49403_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11926-002-0040-y","volume":"4","author":"T Graven-Nielsen","year":"2002","unstructured":"Graven-Nielsen, T. & Arendt-Nielsen, L. Peripheral and central sensitization in musculoskeletal pain disorders: an experimental approach. Curr. Rheumatol. Rep. 4, 313\u2013321 (2002).","journal-title":"Curr. Rheumatol. Rep."},{"key":"49403_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jpain.2007.05.002","volume":"8","author":"P Sarchielli","year":"2007","unstructured":"Sarchielli, P. et al. Increased levels of neurotrophins are not specific for chronic migraine: Evidence from primary fibromyalgia syndrome. J. Pain 8, 737\u2013745 (2007).","journal-title":"J. Pain"},{"key":"49403_CR7","first-page":"1564","volume":"26","author":"SL Giovengo","year":"1999","unstructured":"Giovengo, S. L., Russell, I. J. & Larson, A. A. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J. Rheumatol. 26, 1564\u20139 (1999).","journal-title":"J. Rheumatol."},{"key":"49403_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1097\/AJP.0000000000000194","volume":"31","author":"A Deitos","year":"2015","unstructured":"Deitos, A. et al. Clinical value of serum neuroplasticity mediators in identifying the central sensitivity syndrome in patients with chronic pain with and without structural pathology. Clin. J. Pain 31, 959\u2013967 (2015).","journal-title":"Clin. J. Pain"},{"key":"49403_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.neuint.2013.01.001","volume":"62","author":"B Nugraha","year":"2013","unstructured":"Nugraha, B., Korallus, C. & Gutenbrunner, C. Serum level of brain-derived neurotrophic factor in fibromyalgia syndrome correlates with depression but not anxiety. Neurochem. Int. 62, 281\u2013286 (2013).","journal-title":"Neurochem. Int."},{"key":"49403_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s11064-010-0129-z","volume":"35","author":"L Haas","year":"2010","unstructured":"Haas, L., Portela, L. V. C., B\u00f6hmer, A. E., Oses, J. P. & Lara, D. R. Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia. Neurochem. Res. 35, 830\u2013834 (2010).","journal-title":"Neurochem. Res."},{"key":"49403_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jpsychires.2006.02.007","volume":"41","author":"C Laske","year":"2007","unstructured":"Laske, C. et al. Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J. Psychiatr. Res. 41, 600\u2013605 (2007).","journal-title":"J. Psychiatr. Res."},{"key":"49403_CR12","doi-asserted-by":"publisher","first-page":"1744-8069-10-46","DOI":"10.1186\/1744-8069-10-46","volume":"10","author":"Simone Azevedo Zanette","year":"2014","unstructured":"Zanette, S. A. et al. Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgia. Mol. Pain 10 (2014).","journal-title":"Molecular Pain"},{"key":"49403_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cyto.2016.05.011","volume":"84","author":"A Ranzolin","year":"2016","unstructured":"Ranzolin, A. et al. Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia - A controlled cross-sectional study. Cytokine 84, 25\u201328 (2016).","journal-title":"Cytokine"},{"key":"49403_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/01.j.pain.0000460350.30707.8d","volume":"156","author":"J Tesarz","year":"2015","unstructured":"Tesarz, J. et al. Distinct quantitative sensory testing profiles in nonspecific chronic back pain subjects with and without psychological trauma. Pain 156, 577\u2013586 (2015).","journal-title":"Pain"},{"key":"49403_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-13-136","volume":"13","author":"A Gerhardt","year":"2012","unstructured":"Gerhardt, A. et al. Subgroups of musculoskeletal pain patients and their psychobiological patterns \u2013 The LOGIN study protocol. BMC Musculoskelet. Disord. 13, 136 (2012).","journal-title":"BMC Musculoskelet. Disord."},{"key":"49403_CR16","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1097\/j.pain.0000000000000586","volume":"157","author":"J Tesarz","year":"2016","unstructured":"Tesarz, J., Eich, W., Treede, R.-D. & Gerhardt, A. Altered pressure pain thresholds and increased wind-up in adult patients with chronic back pain with a history of childhood maltreatment: a quantitative sensory testing study. Pain 157, 1799\u20131809 (2016).","journal-title":"Pain"},{"key":"49403_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/j.pain.0000000000000777","volume":"158","author":"A Gerhardt","year":"2017","unstructured":"Gerhardt, A., Eich, W., Treede, R.-D. & Tesarz, J. Conditioned pain modulation in patients with nonspecific chronic back pain with chronic local pain, chronic widespread pain, and fibromyalgia. Pain 158, 430\u2013439 (2017).","journal-title":"Pain"},{"key":"49403_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond, A. S. & Snaith, R. P. The hospital anxiety and depression scale (HADS). Acta Psychiatr. Scand. 67, 361\u2013370 (1983).","journal-title":"Acta Psychiatr. Scand."},{"key":"49403_CR19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.neurobiolaging.2006.06.011","volume":"28","author":"AA Ziegenhorn","year":"2007","unstructured":"Ziegenhorn, A. A. et al. Serum neurotrophins-A study on the time course and influencing factors in a large old age sample. Neurobiol. Aging 28, 1436\u20131445 (2007).","journal-title":"Neurobiol. Aging"},{"key":"49403_CR20","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.euroneuro.2012.09.003","volume":"23","author":"AF Buchmann","year":"2013","unstructured":"Buchmann, A. F. et al. BDNF Val 66 Met and 5-HTTLPR genotype moderate the impact of early psychosocial adversity on plasma brain-derived neurotrophic factor and depressive symptoms: A prospective study. Eur. Neuropsychopharmacol. 23, 902\u2013909 (2013).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"49403_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul, F., Erdfelder, E., Lang, A. & Buchner, A. G * Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175\u2013191 (2007).","journal-title":"Behav. Res. Methods"},{"key":"49403_CR22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/01621459.1995.10476572","volume":"90","author":"RE Kass","year":"1995","unstructured":"Kass, R. E. & Raftery, A. E. Bayes Factors. J. Am. Stat. Assoc. 90, 773\u2013795 (1995).","journal-title":"J. Am. Stat. Assoc."},{"key":"49403_CR23","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/S0028-3908(98)00141-5","volume":"37","author":"W Pan","year":"1998","unstructured":"Pan, W., Banks, W. A., Fasold, M. B., Bluth, J. & Kastin, A. J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37, 1553\u20131561 (1998).","journal-title":"Neuropharmacology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49403-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49403-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49403-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T13:52:31Z","timestamp":1671285151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49403-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,20]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["49403"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-49403-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,20]]},"assertion":[{"value":"9 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13667"}}